Proposal and exploration of a novel score to quantify patient‐perceived burden of inflammatory bowel disease under routine care
Internal Medicine Journal · 2025
DOI: 10.1111/imj.16634 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Joseph L Pipicella und 6 weiteren Autor:innen. Beteiligte Einrichtung: Crohn's Colitis Cure, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Cost of Illness, Inflammatory Bowel Diseases. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Janssen-Cilag Pty Ltd.
Abstract (Originalsprache)
Background
The burden of inflammatory bowel disease (IBD) is often reported on from a system or cost viewpoint. We created and explored a novel patient‐perceived burden of disease (PPBoD) score in a large Australasian cohort.
Aim
To create and explore a novel patient‐perceived burden of disease (PPBoD) score in a large Australasian cohort, and correlate PPBoD scores with demographics, disease and treatment factors.
Methods
The Crohn Colitis Care Registry was interrogated in October 2023. Data from adults with IBD with an outpatient care encounter in the last 14 months among 17 centres were included. A novel PPBoD score was designed for ulcerative colitis (UC), Crohn disease (CD) and IBD‐unclassified (IBDU). Correlations between PPBoD scores and demographics, disease and treatment factors were examined.
Results
Of those with adequate data, 46.7% (2653/5685) had no PPBoD, 34.6% (1969/5685) had mild, 11.3% (641/5685) had moderate and 7.4% (422/5685) had significant PPBoD. New Zealanders were more likely to have higher PPBoD compared to Australians ( P = 0.047). Greater PPBoD was seen in patients with CD and IBDU compared to patients with UC ( P < 0.001) and females were more likely to have significant PPBoD (8.7%) than males (6.1%) ( P < 0.001). People with no or mild PPBoD were more likely to be on advanced therapies (55.7% and 59.5% respectively) than those with significant PPBoD (46.3%) ( P < 0.001). The proportion of people on advanced therapies in Australia was higher than in New Zealand (61.2% vs 38.5% respectively, P < 0.001). Steroid usage was significantly higher in people with greater PPBoD (significant BoD 7.1% vs no BoD 1.1%; P < 0.001).
Conclusion
Most of this real‐world care cohort had no or mild PPBoD. Data suggest that higher PPBoD levels may be resolved by appropriate therapeutic escalations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Crohn's Colitis Cure, Sydney, New South Wales, Australia.
- Medicine & Health (South Western Sydney Clinical School), University of New South Wales, Sydney, New South Wales, Australia.
- Gastroenterology, Hepatology and Inflammatory Bowel Disease Research Group, Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia.
- Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia.
- Department of Surgical Specialties and Anesthesia, Lyell McEwin Hospital, Adelaide, South Australia, Australia.
- Medical Information Office, SA Health, Adelaide, South Australia, Australia.
ORCID-Profile: Joseph L Pipicella
Förderung
- Janssen-Cilag Pty Ltd
Zitieren
APA
Pipicella, J. L., Gu, B., McNamara, J., Wilson, W., Palmer, L. J., Connor, S. J., & Andrews, J. M. (2025). Proposal and exploration of a novel score to quantify patient‐perceived burden of inflammatory bowel disease under routine care. Internal Medicine Journal. https://doi.org/10.1111/imj.16634
Vancouver
Pipicella JL, Gu B, McNamara J, Wilson W, Palmer LJ, Connor SJ, et al. Proposal and exploration of a novel score to quantify patient‐perceived burden of inflammatory bowel disease under routine care. Internal Medicine Journal. 2025. doi:10.1111/imj.16634
BibTeX
@article{Pipicella2025,
author = {Pipicella, Joseph L and Gu, Bonita and McNamara, Jack and Wilson, William and Palmer, Lyle J and Connor, Susan J and Andrews, Jane M},
title = {Proposal and exploration of a novel score to quantify patient‐perceived burden of inflammatory bowel disease under routine care},
journal = {Internal Medicine Journal},
year = {2025},
doi = {10.1111/imj.16634}
}
EUVIMED